A strategic partnership agreement with Pfizer
The Trust manages the five NHS adult hospitals in Sheffield and works very closely with the University of Sheffield, among others, to ensure it is at the cutting edge of medical research and development. Pfizer Ltd, a global pharmaceutical company, has a comprehensive R&D strategy and works extensively with leading scientists and physicians in universities and academic medical centres.
The strategic partnership agreement was established to outline more explicitly how the partners can work together. It is strongly supported by senior managers in the partner organisations. Working together will help the partners to share experience and expertise around service redesign, demonstrate the value of medicines in the patient pathway, translate innovation in health care to the patient, and promote health care research in the UK. These aims are achieved by focusing on three key areas of interest: management and leadership, health service delivery, health service and pharmaceutical research. A Strategy Executive involving people from both Pfizer Ltd and the Trust promotes and allocates resources to projects in these areas.
One successful project conducted through the agreement had researchers jointly exploring service efficiencies in endocrinology. This has improved the quality of patient care and reduced unnecessary follow-ups for patients. Another collaboration created and put in place a leadership development programme to support the effective running of Sheffield Teaching Hospital’s pharmacy department.
Thanks to Pfizer’s knowledge and expertise, both the Trust and the University have developed a better understanding of the pharmaceutical industry’s commercial needs. This has enhanced the success of research proposals. A hospital managers’ programme to share best practice and leadership skills across the local area has been established, and the agreement has also led to the sharing of leadership skills and insights between executives in both organisations. Links created by the agreement mean that Sheffield was chosen as a site for a clinical trial in chronic obstructive pulmonary disease (COPD). A valuable research strategy day focused on investigator-initiated research, clinical trials and health economics.